Skip to Content

New CLL Study Supports Inclusion of Venetoclax Plus Obinutuzumab in Treatment Guidelines

Listen to Dr. Othman Al-Sawaf from University of Cologne, explaining why he believes that venetoclax plus obinutuzumab should have a prominent position in the treatment guidelines for CLL, in both elderly and younger patients, as well as fit and unfit patients. Dr. Al-Sawaf’s perspective is based on the compelling data from the CLL14 study, which was highlighted as one of the seven particularly noteworthy abstracts at EHA23.

Othman Al-Sawaf

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top